BRD2 and neoplasm: Response to NAT in PDAC is currently evaluated preoperatively based on imaging and serum carbohydrate antigen 19–9 (CA 19–9) levels and postoperatively by histological assessment of tumour regression (Springfeld et al. 2023; Gugenheim et al. 2022; Holm et al. 2024).